Clinical trialPhase 2 / Phase 3Withdrawn
A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
A Phase II/III Adaptive Study to Evaluate the Safety and Efficacy of Oral Methylnaltrexone Bromide Tablets in Subjects With Advanced Pancreatic Cancer
- Outcome
- Stopped earlyDue to pandemic challenges and consideration of a different study design in the future. (Other)
- Phase
- Phase 2 / Phase 3
- Status
- Withdrawn
- Study type
- Interventional
- Planned start
- 6 January 2020
- Planned end
- 15 October 2023
- Enrollment
- 0 participants
- Sites
- 1
- Primary outcomes
- Overall Survival
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 7 May 2021
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is an adaptive design study. During the first phase of the study, participants will be randomized in 2:1 ratio to receive either MNTX 450 milligrams (mg) once daily (QD) or placebo. An interim analysis will be performed for futility and at that point a higher dosage regimen may be utilized for the active treatment group if the futility criteria are met. For the second stage of the study, interim analyses will be conducted for futility and sample size reassessment.